Tue, Jan 30, 2024
The company's consolidated revenue from operations also saw a rise of 7.05 per cent as it also beat analysts' estimates to rise to Rs 7237 crore in Q3 from Rs 6760 crore in the same quarter last fiscal. The revenue was above the research estimate of Rs 6914 crore.
More >
Mon, Jan 29, 2024
Zee Business research estimates the pharma firm to report a five per cent jump in its consolidated profit after tax (PAT) to Rs 1310 crore in the December quarter against Rs 1247 crore in the same quarter last fiscal.
Wed, Jan 25, 2023
Dr Reddy's Q3 results: Dr Reddy's gross margin witnessed a 59.2 per cent rise from 53.8 per cent reported in the year-ago period.
Sat, Feb 04, 2017
GV Prasad, Co-chairman of Dr Reddy's Laboratories said, "Our performance in Q3 has delivered a modest sequential revenue growth of 3% over the previous quarter. Our EBITDA has improved significantly from the last quarter to Rs 8.8 billion, on the back of enhanced emphasis on operational efficiencies and controlling of SG&A cost across all our business."
Thu, Jan 12, 2017
Piyush Nahar and Anurag Mantry analysts of Jefferies said, “We expect another muted quarter for the pharma sector led by weakness in US business. USFDA inspections and pricing in US market will continue to dominate the results. Recent comments from global peers have indicated that pricing scenario will likely remain unchanged in 2017.”
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
